These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
944 related articles for article (PubMed ID: 36268520)
1. Management of Axial Spondyloarthritis - Insights into Upadacitinib. Braun J; Kiltz U; Baraliakos X Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520 [TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Keeling S; Maksymowych WP Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642 [TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis. Braun J; Kiltz U; Baraliakos X Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657 [TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479 [TBL] [Abstract][Full Text] [Related]
6. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Fukui S; Kawaai S; Sawada H; Kishimoto M Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181 [TBL] [Abstract][Full Text] [Related]
7. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? Akkoc N; Khan MA Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185 [TBL] [Abstract][Full Text] [Related]
8. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210 [TBL] [Abstract][Full Text] [Related]
9. Emerging treatment options for spondyloarthritis. Torgutalp M; Poddubnyy D Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316 [TBL] [Abstract][Full Text] [Related]
10. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. Malaviya AN; Kalyani A; Rawat R; Gogia SB Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961 [TBL] [Abstract][Full Text] [Related]
11. Treatment of axial spondyloarthritis: an update. Danve A; Deodhar A Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385 [TBL] [Abstract][Full Text] [Related]
12. Advances in pharmacotherapies for axial spondyloarthritis. Toussirot E Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247 [TBL] [Abstract][Full Text] [Related]
14. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Deodhar A; Strand V; Kay J; Braun J Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406 [TBL] [Abstract][Full Text] [Related]
15. Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis. Hansmaennel A; Fakih O; Gerazime A; Prati C; Chouk M; Wendling D; Verhoeven F Clin Rheumatol; 2024 Mar; 43(3):1045-1052. PubMed ID: 38158505 [TBL] [Abstract][Full Text] [Related]
16. The Future of Axial Spondyloathritis Treatment. Maguire S; Sengupta R; O'Shea F Rheum Dis Clin North Am; 2020 May; 46(2):357-365. PubMed ID: 32340707 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Janus kinase inhibitors in axial spondyloarthritis. Daoud A; Magrey MN Indian J Dermatol Venereol Leprol; 2023 Jun; ():1-9. PubMed ID: 37436016 [TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis. Bhatnagar S; Eckert D; Stodtmann S; Song IH; Wung P; Liu W; Mohamed MF Clin Transl Sci; 2024 Feb; 17(2):e13733. PubMed ID: 38344875 [TBL] [Abstract][Full Text] [Related]
20. New developments in ankylosing spondylitis-status in 2021. Klavdianou K; Tsiami S; Baraliakos X Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi29-vi37. PubMed ID: 34951921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]